Taysha Gene Therapies (TSHA) Other financing activities (2022 - 2026)

Taysha Gene Therapies has disclosed Other financing activities across 5 years of filings, most recently posting $19000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at $19000.0, up 123.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$238000.0 (down 643.75% YoY), and the FY2025 annual result was -$337000.0, down 1972.22% from the prior year.
• Other financing activities came in at $19000.0 for Q1 2026 at Taysha Gene Therapies, up from -$90000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $1.1 million in Q4 2022 to a low of -$543000.0 in Q2 2023.
• The 5-year median for Other financing activities is -$30000.0 (2024), against an average of -$10058.8.
• Across the five-year window, Other financing activities slumped 270.18% in 2023 and jumped 850.0% in 2024, its largest moves.
• Taysha Gene Therapies' Other financing activities stood at $1.1 million in 2022, then slumped by 97.75% to $24000.0 in 2023, then surged by 850.0% to $228000.0 in 2024, then sank by 139.47% to -$90000.0 in 2025, then soared by 121.11% to $19000.0 in 2026.
• The last three Other financing activities figures came in at $19000.0 (Q1 2026), -$90000.0 (Q4 2025), and -$285000.0 (Q3 2025), per Business Quant data.